NeuroBo reveals DA-1726 safe and well tolerated
NeuroBo Pharmaceuticals has revealed positive top-line safety, tolerability and dose-linear pharmacokinetics (PK) data from the single...
top of page
Browse by category
Search
First patient dosed NeuroBo Pharmaceuticals’ Phase 1 clinical trial evaluating DA-1726 for the treatment of obesity
NeuroBo Pharmaceuticals has dosed the first patient in the multiple ascending dose (MAD) Part 2 of its Phase 1 clinical trial of DA-1726,...
NeuroBo Pharmaceuticals to initiate Phase 1 Clinical Trial of DA-1726 for obesity
The FDA has cleared NeuroBo Pharmaceuticals’ Investigational New Drug (IND) application for DA-1726, a novel, dual oxyntomodulin (OXM)...
NeuroBo submits IND to FDA for DA-1726 for the treatment of obesity
NeuroBo Pharmaceuticals has submitted an Investigational New Drug (IND) application to the FDA to support a Phase 1 clinical trial of...
Browse by tag
bottom of page